Royal Bank of Canada
TXMD icon

Royal Bank of Canada’s TherapeuticsMD TXMD Stock Holding History

Royal Bank of Canada’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-10
Closed -$1K – 7132
2019
Q2 		$1K Buy
10
+6
+150% +$1.08K ﹤0.01% 6748
2019
Q1 		$1K Sell
4
-26
-87% -$6.88K ﹤0.01% 6685
2018
Q4 		$6K Buy
+30
New +$7.32K ﹤0.01% 6114

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royal Bank of Canada's TXMD Position: Q1 2026 in Review

Royal Bank of Canada increased its TherapeuticsMD (TXMD) stake by 23% in Q1 2026, buying an estimated $81 and bringing the position to 190 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7711.

Royal Bank of Canada first reported a position in TXMD in Q3 2013 and has held it in 50 quarters since. The position peaked at $299K in Q1 2022. 49 funds tracked by Wall St. Rank hold TXMD as of Q1 2026.

  • Royal Bank of Canada held 190 shares of TherapeuticsMD worth $0 as of Q1 2026.
  • Royal Bank of Canada bought 36 TherapeuticsMD shares in Q1 2026, an estimated $81.
  • TherapeuticsMD made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7711 holding.
  • Royal Bank of Canada first reported a position in TherapeuticsMD in Q3 2013 and has held it in 50 quarters since.
  • Royal Bank of Canada's TherapeuticsMD position peaked at $299K in Q1 2022.
  • 49 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.